Condition: Head and Neck Cancer · Lymphedema of the Head and Neck · Sponsor: Abramson Cancer Center at Penn Medicine
The U.S. Food and Drug Administration approved photobiomodulation therapy (PBMT) as a treatment for breast cancer-related arm lymphedema (BCRL) in 2006. The investigators conducted two pilot clinical trials. Results demonstrated the feasibility, acceptability, and preliminary efficacy of PBMT for the treatment of chronic lymphedema in head and neck cancer (HNC) survivors. The objective of this study is to further investigate and confirm the positive effects of PBMT on HNC-related chronic lymphedema.
This description comes directly from the study's public registry record.
Jie Deng, PhD · 2155732393 · jiedeng@nursing.upenn.edu
Sarah Latimore, MS · 2155732393
Always discuss trial participation with your own doctor first.
| University of Pennsylvania Abramson Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06837480